Litigation
Mar. 24, 2015
Amgen gearing up to appeal judge's decision to deny injunction in biosimilar drug case
Amgen's attorneys are weighing an appeal to a U.S. District Court decision late last week that turned down the company's request for a preliminary injunction against Sandoz's sale of a drug similar to Amgen's blockbuster Neupogen.
Daily Journal Staff Writer
Attorneys for Amgen Inc. are likely to pursue an appeal to a decision late last week that turned down the company's request for a preliminary injunction against Sandoz Inc.'s sale of a drug similar to Amgen's popular Neupogen treatment.
San Francisco-based Vernon M. Winters, a partner with Sidley Austin LLP, and Nicholas P. Groombridge, a partner with Paul, Weiss, Rifkind, Wharton and Garr...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In